Does Medicare cover Ozempic and GLP-1 medications in 2026
Published: January 15, 2026 | Last Updated: January 15, 2026
Author: Sarah Mitchell, Healthcare Cost Writer | Medical Advisory Board
If you're a Medicare beneficiary considering GLP-1 medications like Ozempic, Wegovy, or Mounjaro in 2026, you're likely wondering one thing: will Medicare actually pay for this? The answer isn't simple—and it depends on several critical factors that could mean the difference between a $15 copay and a $1,200 monthly bill. I've spent years helping patients navigate these decisions, and what I've learned is that GLP-1 coverage through Medicare has become increasingly nuanced. While some beneficiaries are seeing these life-changing medications covered, others are hitting unexpected walls based on their specific diagnosis, their chosen plan, and whether they're using the drug for diabetes or weight loss. Understanding the 2026 landscape requires getting into the details—so let's break down exactly what Medicare covers, what it doesn't, and how you can maximize your benefits.
Understanding Medicare Coverage by Indication and Plan Type
The most important factor determining your GLP-1 coverage isn't just which medication you want—it's why you're taking it. Medicare Part D, which covers prescription drugs for approximately 28 million beneficiaries, treats GLP-1 medications differently based on your diagnosis. This distinction has major cost implications.
Type 2 Diabetes Coverage
If you have type 2 diabetes, you're in a much stronger position. As of 2026, approximately 78% of Medicare Part D plans include at least one GLP-1 medication on their formulary for diabetes management. Ozempic (semaglutide) specifically is covered by roughly 72% of standard Part D plans, with typical copays ranging from $15 to $75 per month for a 30-day supply, depending on your plan's tier structure and whether you're in the coverage gap phase.
However, this coverage comes with conditions. Most plans require prior authorization, meaning your doctor must document that you've tried other diabetes medications first. Additionally, many plans impose quantity limits—restricting coverage to one injection per month, even if your doctor prescribes weekly injections.
Weight Loss (Obesity) Indication Coverage
The story changes dramatically if you're using GLP-1 medications for weight loss without a diabetes diagnosis. Wegovy (semaglutide for weight loss) and Zepbound (tirzepatide for weight loss) face significantly more restrictive coverage. Only approximately 23% of Medicare Part D plans cover GLP-1 medications for obesity management as of 2026. When coverage is available, out-of-pocket costs are substantially higher, typically ranging from $100 to $250 per month in copays, and many plans require documented BMI thresholds or weight-related comorbidities before approval.
This coverage disparity reflects ongoing policy debates about whether weight loss medications should be classified as therapeutic treatments covered by insurance or elective cosmetic interventions. Most traditional Medicare Part D plans still lean toward the latter interpretation.
Part B Considerations
It's worth noting that some GLP-1 medications may fall under Medicare Part B (medical insurance) rather than Part D in specific contexts—particularly in hospital or dialysis clinic settings. If you're receiving a GLP-1 medication as part of your treatment in a covered facility, different cost-sharing rules apply, typically involving a 20% coinsurance after your deductible is met.
Out-of-Pocket Costs and the Coverage Gap Impact
Understanding the actual dollars you'll pay requires navigating Medicare's complex cost structure, which includes different phases of coverage with varying copay amounts.
The Standard Part D Coverage Phases in 2026
After your annual $505 deductible (2026 figure), you enter the initial coverage phase where most beneficiaries pay standard copays. For diabetes-indicated GLP-1s like Ozempic, this typically means $15–$45 copays depending on whether the drug is on Tier 1, 2, or 3 of your plan's formulary. Most GLP-1 medications are classified as Tier 3 or 4 (specialty tier), pushing the copay toward $75–$150 per 30-day supply.
The problematic part: the "donut hole" or coverage gap. Once you and your insurance combined have spent $5,735 on covered drugs in 2026, you enter the gap. Here's where it gets expensive. In the coverage gap, you typically pay 25% of the drug's negotiated price out-of-pocket. For a specialty GLP-1 medication with a negotiated price of $1,000 per month, that's $250/month directly from your pocket until you reach catastrophic coverage limits.
However, there's a silver lining: the $2,000 out-of-pocket maximum for coverage gap costs means that once you've spent $2,000 in the gap, you reach catastrophic coverage and pay only 5% coinsurance for the rest of the year.
Real-World Cost Example
Let's say you're a beneficiary taking Ozempic for type 2 diabetes on a standard Part D plan covering the medication at $75 monthly copay: January through May (5 months) = $375 in copays. By June, you've hit the $5,735 threshold and enter the coverage gap. Your Ozempic's negotiated price is $1,000/month. June through August, you pay 25% = $250/month. By September, you've spent $2,000 in the gap and reach catastrophic coverage. September through December, you pay 5% coinsurance = $50/month. Total annual out-of-pocket: roughly $1,975.
Coverage Limitations and How to Navigate Them
Even when Medicare Part D covers your GLP-1 medication, several limitations can affect access and affordability.
Prior Authorization Requirements
Approximately 68% of Part D plans require prior authorization for GLP-1 medications, particularly for weight loss indications. This means your doctor must submit paperwork proving medical necessity before the pharmacy will fill your prescription. The approval process typically takes 5–10 business days, though expedited reviews are sometimes available for established patients.
Quantity and Refill Limits
Many plans limit coverage to one GLP-1 injection per month, even if prescribed weekly. Some plans have implemented "fail-first" or step-therapy requirements, mandating that patients try and fail on other diabetes medications (like metformin or sulfonylureas) before GLP-1 approval. These restrictions can delay your treatment by months.
Formulary Exclusions
While major GLP-1 medications are increasingly common on Part D formularies, complete exclusions still exist. Some regional or low-premium plans exclude Wegovy entirely or limit GLP-1 access to diabetes-only indications. This is why checking your specific plan's formulary is essential.
Critical action item: Use the Medicare.gov Plan Finder to compare GLP-1 coverage across plans in your area before enrollment. Filter specifically by your medication and indication to see which plans cover it and at what cost.
Step Therapy and Authorizations
Some plans require documented failure on lower-cost diabetes medications before authorizing GLP-1 coverage. This can add 2–3 months to your treatment timeline while you try and fail on required alternatives.
Important Disclaimer: GLP-1 coverage varies